Table 1. Baseline Characteristics of 751 patients with MDS.
| Variables | n | Translocation (n = 40) | No translocation (n = 711) | P-value | |
|---|---|---|---|---|---|
| Age (years) | <60 | 286 | 10 (25.0) | 276 (38.8) | 0.08 |
| ≥60 | 465 | 30 (75.0) | 435 (61.2) | ||
| Gender | Male | 457 | 23 (57.5) | 434 (61.0) | 0.66 |
| Female | 294 | 17 (42.5) | 277 (39.0) | ||
| ANC (x 109/L) (median, range) | 0.86 (0.67–6.99) | 1.20 (0–52.99) | 0.36 | ||
| Hb (g/dL) (median, range) | 8.1 (4.4–14.5) | 8.5 (2.8–15.9) | 0.30 | ||
| Platelets (x 1012/L) (median, range) | 72 (6–288) | 76 (1–4120) | 0.33 | ||
| BM blasts (%) (median, range) | 5.4 (0–19.8) | 2.5 (0–20) | <0.01 | ||
| Diagnosis | RARS | 28 | 0 | 28 (4.0) | <0.01 |
| RCUD | 115 | 2 (5.0) | 113 (16.0) | ||
| RCMD | 223 | 9 (22.5) | 214 (30.3) | ||
| RAEB-1 | 149 | 9 (22.5) | 140 (19.8) | ||
| RAEB-2 | 138 | 18 (45.0) | 120 (17.0) | ||
| MDS-U | 89 | 2 (5.0) | 87 (12.3) | ||
| Del5q | 5 | 0 | 5 (0.7) | ||
| Unknown | 4 | 0 | 4 (0.6) | ||
| IPSS | Low | 140 | 0 | 140 (19.7) | <0.01 |
| Int-1 | 419 | 7 (17.5) | 412 (57.9) | ||
| Int-2 | 150 | 20 (50) | 130(18.3) | ||
| High | 42 | 13 (32.5) | 29 (4.1) | ||
| IPSS-R | Very low | 51 | 0 | 51 (7.2) | <0.01 |
| Low | 221 | 1 (2.5) | 220 (30.9) | ||
| Intermediate | 219 | 4 (10.0) | 215 (30.2) | ||
| High | 152 | 9 (22.5) | 143 (20.1) | ||
| Very high | 108 | 26 (65.0) | 82 (11.5) | ||
| HMA | Yes | 381 | 27 (67.5) | 354 (49.8) | 0.03 |
| No | 370 | 13 (32.5) | 347 (50.2) | ||
| HSCT | Yes | 83 | 3 (7.5) | 80 (11.3) | 0.46 |
| No | 668 | 37 (92.5) | 631 (88.7) | ||
Abbreviations: MDS, myelodysplastic syndrome; ANC, absolute neutrophil count; Hb, hemoglobin; BM, bone marrow; WHO, World Health Organization; RARS, refractory anemia with ringed sideroblasts; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blast; MDS-U, MDS unclassified; IPSS, International Prognostic Scoring System; IPSS-R, Revised IPSS; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation.